Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195528 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
A Phase 3 study, sponsored by Phathom Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 776
- Enrollment target
NCT05195528 is a Phase 3 study that has completed, run by Phathom Pharmaceuticals. The registered enrollment target is 776 participants.
The verdict
NCT05195528, a Phase 3 study, has completed, sponsored by Phathom Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 776 participants
- Enrollment target
Study Summary
The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily \[QD\]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
Interventions
- DRUG Placebo
- DRUG Vonoprazan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 776 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2023-05-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05195528
The ClinicalTrials.gov registry entry for NCT05195528 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 776 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phathom Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05195528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05195528 about?
NCT05195528 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)". The primary objectives of this study are to assess the efficacy of vonoprazan (10 mg and 20 mg once daily \[QD\]) compared to placebo (QD) in relief of heartburn over 4 weeks in participants with NERD.
What is the current status of trial NCT05195528?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 776 participants. The study started on 2022-01-17. Estimated completion is 2023-05-17.
What interventions are being tested in trial NCT05195528?
The interventions under investigation include: Placebo (DRUG), Vonoprazan (DRUG).
Who is sponsoring clinical trial NCT05195528?
This trial is sponsored by Phathom Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.